FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

New Delhi: Food regulator FSSAI has suspended the licence of Dior Pharmaceuticals for multiple violations at its nutraceutical factory.

In a social media post on Thursday, FSSAI observed “serious non-compliances” during the inspection of the manufacturing unit in Punjab.

“The Nutraceutical Manufacturing Unit was found to be operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS),” the Food Safety and Standards Authority of India (FSSAI) said.

Stating that the deficiencies pose a significant risk to public health, FSSAI said there has been a gross non-compliance with the FSS Act, 2006.

“The FSSAI Licence has been suspended with immediate effect. The FBO (food business operator) has been directed to immediately cease all operations until all deficiencies are rectified and compliance is established to the satisfaction of the Competent Authority,” the regulator said.

Giving details about major and critical non-conformities observed during the inspection, FSSAI said that the regulatory non-compliances were related to infrastructure; sanitation and housekeeping; pest control; storage and handling practices; process controls; personnel hygiene; water quality monitoring; and maintenance of records, among other issues.

The regulator further said that there is a serious failure on the part of the company in ensuring the safety, quality and traceability of food products.

In the last few months, FSSAI has cracked down on many energy drink and alcoholic beverage companies for misleading claims and labelling. It has also issued notices to many e-commerce platforms.

These actions are based on consumer complaints, suo motu cognisance, and regular enforcement activities of food safety officers.

FSSAI posts updates about these enforcement actions against food business operators and e-commerce companies through social media platforms, including Instagram.

“The Nutraceutical Manufacturing Unit was found to be operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS),” the Food Safety and Standards Authority of India (FSSAI) said.

Stating that the deficiencies pose a significant risk to public health, FSSAI said there has been a gross non-compliance with the FSS Act, 2006.

“The FSSAI Licence has been suspended with immediate effect. The FBO (food business operator) has been directed to immediately cease all operations until all deficiencies are rectified and compliance is established to the satisfaction of the Competent Authority,” the regulator said.

Giving details about major and critical non-conformities observed during the inspection, FSSAI said that the regulatory non-compliances were related to infrastructure; sanitation and housekeeping; pest control; storage and handling practices; process controls; personnel hygiene; water quality monitoring; and maintenance of records, among other issues.

The regulator further said that there is a serious failure on the part of the company in ensuring the safety, quality and traceability of food products.

In the last few months, FSSAI has cracked down on many energy drink and alcoholic beverage companies for misleading claims and labelling. It has also issued notices to many e-commerce platforms.

These actions are based on consumer complaints, suo motu cognisance, and regular enforcement activities of food safety officers.

FSSAI posts updates about these enforcement actions against food business operators and e-commerce companies through social media platforms, including Instagram.

Related Posts

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

New Delhi: The Centre has disclosed a significant enforcement action against hospitals found violating the guidelines of the Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), with 2,359 hospitals de-empanelled, 1,200…

NHS backs delayed‑release treatment for cystinosis

Decision expands options for eligible patients NHS England has recommended delayed‑release mercaptamine bitartrate for routine commissioning for eligible patients aged one year and above with nephropathic cystinosis. The decision provides…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

AB-PMJAY Crackdown: 2,359 Hospitals De-empanelled, 1,200 Suspended for Violating Scheme Guidelines, Nadda Tells Lok Sabha

NHS backs delayed‑release treatment for cystinosis

NHS backs delayed‑release treatment for cystinosis

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Promotion of Drug Inspectors (Medical Devices) raises hopes of Effective Regulation & Patient Safety

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Maharashtra FDA Permanently Cancels Licence of Pune Ayurvedic Drug Manufacturer Over Serious GMP and Quality Violations

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Telangana DCA Seizes Gabapentin Tablets Falsely Sold as Nutraceuticals in Hyderabad

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry

Massive Blood Wastage in Gujarat: Over 85,000 Units Discarded Due to Storage Lapses and Expiry